NewsBenzingaOncolytics Biotech anuncia que su grupo 4 del ensayo GOBLET de fase 1/2 de pelareorep en combinación con atezolizumab no logró alcanzar la mediana de supervivencia global Oncolytics Biotech anuncia que su grupo 4 del ensayo GOBLET de fase 1/2 de pelareorep en combinación con atezolizumab no logró alcanzar la mediana de supervivencia global Benzinga 2026.10.27 13:32 (GMT+0) Open on Benzinga Other news Google Gets Court Approval to Buy Bankrupt Spirit Airlines’ Internal Data for $10 Million to Train AI Models Despite Employee Privacy Concerns Reported Earlier, 'Alphabet’s Waymo Pulls Robotaxis Off Freeways After California Ban; Robotaxi services are continuing to operate on surface streets' - WSJ TD Cowen Maintains Buy Rating on Sharplink With $13 Price Target EXCLUSIVE: Anthropic's Post-IPO Rise Could Reveal 2 Different Paths for AI Stocks: 'Rotation' or A 'Healthier' Rally, Wall Street Expert Says Reported Earlier, EnQuest Sells UK Upstream Business To NEO NEXT+ For Up To $960M Bill Gates’ Foundation Keeps Cutting Warren Buffett's Berkshire Hathaway Stake, Adds 1.36 Million Dollar Tree Shares In Q3
Google Gets Court Approval to Buy Bankrupt Spirit Airlines’ Internal Data for $10 Million to Train AI Models Despite Employee Privacy Concerns
Reported Earlier, 'Alphabet’s Waymo Pulls Robotaxis Off Freeways After California Ban; Robotaxi services are continuing to operate on surface streets' - WSJ
EXCLUSIVE: Anthropic's Post-IPO Rise Could Reveal 2 Different Paths for AI Stocks: 'Rotation' or A 'Healthier' Rally, Wall Street Expert Says
Bill Gates’ Foundation Keeps Cutting Warren Buffett's Berkshire Hathaway Stake, Adds 1.36 Million Dollar Tree Shares In Q3